Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.58 |
| ▸ | ALDH2 | P05091 | 7/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | MAOB | P27338 | 6/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747968 | 0.98 | ALB (0.68) | ALBPPARANR5A1ALDH2MAOA | |
| SCHEMBL2158826 | 0.98 | ALB (0.68) | ALBPPARANR5A1ALDH2MAOA | |
| SCHEMBL12534514 | 0.98 | ALB (0.68) | ALBPPARANR5A1ALDH2MAOA | |
| SCHEMBL1271045 | 0.91 | ESR1 (0.59) | ALBPPARANR5A1ESR1 | |
| SCHEMBL29141429 | 0.91 | PPARA (0.71) | ALBPPARAPLA2G4B | |
| SCHEMBL21073528 | 0.91 | PPARA (0.71) | ALBPPARAPLA2G4B | |
| SCHEMBL31448424 | 0.91 | PPARA (0.71) | ALBPPARAPLA2G4B | |
| SCHEMBL31448470 | 0.89 | PPARA (0.73) | ALBPPARAPLA2G4B | |
| SCHEMBL2468006 | 0.85 | L3MBTL1 (0.69) | ALBPPARANR5A1ESR1 | |
| SCHEMBL25228768 | 0.83 | PPARA (0.72) | ALBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030271-B2 | Delivery agents comprising 8-(4-hydroxyphenoxy)octanoic acid, 8-(N-2-hydroxy-4-methoxybenzoyl)-aminocaprylic acid, N-(8-[2-hydroxybenzoyl]-amino) caprylic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)octanoic acid, and/or 4-[(2-hydroxy-4-chlorobenzoyl)amino]butanoic acid or salts; Turner's syndrome | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080207513-A1 | Compositions For Buccal Delivery of Human Growth Hormone | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2007005995-A9 | COMPOSITIONS FOR BUCCAL DELIVERY OF HUMAN GROWTH HORMONE | EMISPHERE TECH INC (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007005995-A2 | COMPOSITIONS FOR BUCCAL DELIVERY OF HUMAN GROWTH HORMONE | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207513-A1 | Compositions For Buccal Delivery of Human Growth Hormone | GHRHR, GHSR, GHITM | ALB 315/4885PPARA 3252/4885NR5A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.